3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Solid Tumors
1
Pleural Effusion
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Multiple Myeloma
1
Insulin-Like Growth Factor I, Resistance To
1
Advanced Solid Tumors
1
Interventions
durvalumab
7
Carboplatin
7
Docetaxel
6
Paclitaxel
5
Nivolumab
5
talazoparib
4
linifanib
4
Cisplatin
4
trifluridine tipiracil drug combination
3
tremelimumab
3
tislelizumab
3
depatuxizumab
3
ST 1481
3
S 1 (combination)
3
Panobinostat
3
Gemcitabine
3
zimberelimab
2
toripalimab
2
olaparib
2
motesanib diphosphate
2
mogamulizumab
2
TAS-114
2
Sorafenib
2
Rifampin
2
PM 01183
2
Oxaliplatin
2
MLN 8237
2
Itraconazole
2
Injections
2
Erlotinib Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Solid Tumors
×
dalotuzumab
×
Clear all
NCT00635778
2018-10-09
MK-0646-002
Merck Sharp & Dohme LLC
Phase 1
Completed
50 enrolled
32 charts